|1.||Wang-Weigand, Sherry: 4 articles (03/2009 - 05/2007)|
|2.||Laudon, Moshe: 3 articles (12/2015 - 06/2013)|
|3.||Gobbi, Gabriella: 3 articles (10/2015 - 01/2014)|
|4.||Comai, Stefano: 3 articles (10/2015 - 01/2014)|
|5.||Angeloni, Debora: 3 articles (02/2015 - 01/2005)|
|6.||Fraschini, Franco: 3 articles (02/2015 - 01/2005)|
|7.||Miyamoto, Masaomi: 3 articles (01/2009 - 11/2004)|
|8.||Zhang, Jeffrey: 3 articles (08/2007 - 01/2006)|
|9.||Roth, Thomas: 3 articles (08/2007 - 03/2005)|
|10.||Granados-Soto, Vinicio: 2 articles (10/2015 - 02/2015)|
|1.||Sleep Initiation and Maintenance Disorders (Insomnia)
03/01/2009 - "This study evaluated the long-term efficacy of ramelteon, a selective MT1/MT2 melatonin-receptor agonist used for insomnia treatment. "
07/01/2008 - "Ramelteon is a selective MT1/MT2 melatonin receptor agonist approved by the US Food and Drug Administration for insomnia treatment. "
01/01/2008 - "Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for the treatment of insomnia characterized by difficulty in sleep onset. "
01/01/2008 - "[Drugs for insomnia and improving quality of life (QOL): research and development of ramelteon, an MT1/MT2-receptor agonist]."
08/15/2007 - "To evaluate efficacy and safety of ramelteon (MT1/MT2-receptor [corrected] agonist) in subjects with chronic primary insomnia. "
|2.||Major Depressive Disorder (Major Depressive Disorders)
10/01/2007 - "Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder."
09/01/2011 - "Agomelatine, an MT1/MT2 receptor agonist and 5-HT2C receptor antagonist antidepressant, is known to have beneficial effects on subjective sleep in major depressive disorder patients. "
11/01/2010 - "The objective of this international, 8-week, randomized, double-blind study was to show the superiority of the antidepressant efficacy of agomelatine, the first MT1/MT2 receptor agonist and 5-HT2C receptor antagonist antidepressant, versus fluoxetine in outpatients fulfilling Diagnostic and Statistical Manual of Mental Disorders-volume IV-TR criteria for major depressive disorder of severe intensity, defined by a baseline Hamilton Depression Rating Scale (HAM-D17) total score of at least 25 and CGI severity of illness score of at least 4. Patients received agomelatine 25-50 mg/day (n=252) or fluoxetine 20-40 mg/day (n=263) for 8 weeks. "
02/01/2014 - "Agomelatine is a novel antidepressant that acts as a melatonin MT1 and MT2 receptor agonist and serotonin 5-HT2C receptor antagonist, putatively reversing circadian rhythm disruption in major depressive disorder (MDD) and promoting dendritic neurogenesis in animal models of depression. "
|3.||Alzheimer Disease (Alzheimer's Disease)
02/01/2007 - "The MT2 melatonin receptor subtype is present in human retina and decreases in Alzheimer's disease."
01/01/2005 - "Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease."
01/01/2014 - "These studies demonstrate that MT2 receptors are involved in the pathophysiology and pharmacology of sleep disorders, anxiety, depression, Alzheimer disease and pain and that selective MT2 receptor agonists show hypnotic and anxiolytic properties. "
07/25/2014 - "The significant induction of melatonin MT2 receptor expression by VPA in hippocampal regions involved in learning, memory and/or neural stem cell proliferation, suggests that a combinatorial therapeutic strategy involving VPA together with melatonin or other MT2 agonists, would be beneficial in neurodegenerative disorders such as Alzheimer's disease. "
04/01/2015 - "Deficits of melatonin/MT2 signaling have been found in many neurological disorders, including Alzheimer's disease, the most common cause of dementia in the elderly, suggesting that preservation of the MT2 receptor may be beneficial to these neurological disorders. "
|4.||Circadian Rhythm Sleep Disorders (Delayed Sleep Phase Syndrome)
02/11/2000 - "Genetic polymorphisms of human melatonin 1b receptor gene in circadian rhythm sleep disorders and controls."
01/01/2006 - "In humans, appropriate clinical trials confirm the efficacy of melatonin or melatoninergic agonists for the MT1 and MT2 receptor subtypes in circadian rhythm sleep disorders only. "
11/01/2004 - "Ramelteon (TAK-375) is an MT1/MT2 receptor agonist being studied for the treatment of insomnia and circadian rhythm sleep disorders. "
05/01/2012 - "Melatonin ameliorates neural function by promoting endogenous neurogenesis through the MT2 melatonin receptor in ischemic-stroke mice."
05/01/2012 - "Our aim was to explore the relationship between melatonin's neuroprotective effects and activation of the MT2 melatonin receptor in a murine ischemic-stroke model. "
|3.||S 20098 (agomelatine)
|4.||5-HT2C Serotonin Receptor
|9.||MT1 Melatonin Receptor
|10.||Serotonin (5 Hydroxytryptamine)